Epigral Stock Plummets to New 52-Week Low at Rs. 1442

Epigral, a small-cap player in the specialty chemicals industry, has reached a new 52-week low of Rs. 1442 today, marking a significant downturn for the stock. This decline comes as the company has faced a challenging performance trajectory, with a notable 15.08% drop over the past five days. Today's trading saw the stock underperforming its sector by 5.68%, reflecting broader market trends.
The stock's performance has been consistently below key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained period of weakness. Over the past year, Epigral has recorded a decline of 31.98%, contrasting sharply with the Sensex, which has gained 4.83% during the same timeframe.

Despite a high return on capital employed (ROCE) of 23.84% and a manageable debt-to-EBITDA ratio of 1.46, the company has struggled with long-term growth, evidenced by modest net sales growth of 11.79% annually over the last five years. The recent financial results have also shown a significant drop in profit after tax, further contributing to the stock's current position.